Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

FY25 net profit beat expectations due to higher other income and a lower tax outgo, EBITDA came in slightly below estimates because of increased R&D expenditure.

Cipla's stock experienced a decline in today's session, with the price decreasing by 1.45% to Rs 1498.10. There was high ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Cipla celebrates a significant 30% rise in net profit for Q4 FY25, with revenues growing by 9%. The company emphasizes its ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Cipla CEO says US order to lower drug prices won't impact Indian generic drugmakers. The order is likely to target branded ...

In addition, Jefferies expects Tata Motors to see a tough year ahead with the demand for Indian trucks growing soft and the ...

Shares of several companies, including Cipla, and Tata Steel, among others, will be in the news today on May 14, 2025 ...